Strategic Partnerships Forge Biologics actively collaborates with biotech and pharmaceutical innovators, including recent manufacturing agreements with companies like Fractyl Labs and Affinia Therapeutics, indicating ongoing demand for specialized gene therapy manufacturing services and potential for expanding partnerships.

Growth in Gene Therapy With a focus on developing gene therapies for neuromuscular diseases and a strong presence at industry events such as ASGCT, Forge Biologics demonstrates significant engagement in cutting-edge therapeutics, creating opportunities to offer complementary manufacturing, development, and logistical support to emerging gene therapy developers.

Innovative Infrastructure The launch of the FUEL manufacturing platform highlights Forge’s investment in scalable, advanced manufacturing technologies, which could benefit clients seeking innovative solutions for GMP-compliant production and quicker time-to-market for gene therapies.

Financial Momentum With revenue estimates between $100 million and $250 million secured by $90 million in funding, Forge Biologics has a solid financial foundation, enabling targeted outreach to biotech firms and startups looking for reliable, well-funded manufacturing partners in the competitive gene therapy space.

Customer-Centric Approach Forge’s patients-first philosophy and ongoing development projects suggest a close alignment with client needs, presenting opportunities to position your solutions as integral to their mission to accelerate life-changing therapies to market efficiently.